2018•Sexually Transmitted InfectionsRequires access

Has the introduction of HIV pre-exposure prophylaxis had an impact on HIV post-exposure prophylaxis for sexual exposure prescriptions in men who have sex with men in the UK’s largest health board?

Laura Gillespie, Monica Lowrie, Rebecca Metcalfe

Abstract

In April 2017, the Scottish Medicine Consortium approved emtricitabine/tenofovir disoproxil for use as HIV pre-exposure prophylaxis (PrEP), in combination with safer sex practices.1 National Health Service (NHS) Greater Glasgow and Clyde (GG&C) provides healthcare to >1.2 million people, with a prevalence of HIV in men who have sex with men (MSM) of 5.4%.2 HIV post-exposure prophylaxis for sexual exposure (PEPSE) is available at Sexual Health services …

About this research paper

What this paper is about

Why it matters

OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Pre-exposure prophylaxis, Medicine, Men who have sex with men, Emtricitabine, Post-exposure prophylaxis, Sexual health clinic, Human immunodeficiency virus (HIV), Reproductive health